---
title: Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes
nct_id: NCT00154414
overall_status: COMPLETED
phase: PHASE2
sponsor: Novo Nordisk A/S
study_type: INTERVENTIONAL
primary_condition: Diabetes
countries: Japan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00154414.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00154414"
ct_last_update_post_date: 2017-01-25
last_seen_at: "2026-05-12T06:40:05.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

**Official Title:** Effect of Liraglutide on Glycaemic Control in Japanese Subjects With Type 2 Diabetes.

**NCT ID:** [NCT00154414](https://clinicaltrials.gov/study/NCT00154414)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 226
- **Lead Sponsor:** Novo Nordisk A/S
- **Conditions:** Diabetes, Diabetes Mellitus, Type 2
- **Start Date:** 2005-01
- **Completion Date:** 2006-05
- **CT.gov Last Update:** 2017-01-25

## Brief Summary

This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 74 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy
* 7.0 % =\< HbA1c \< 10.0 %
* Body Mass Index (BMI) \< 30.0 kg/m\^2

Exclusion Criteria:

* Subjects treated with thiazolidinediones or insulin
* Subjects with any serious medical conditions
```

## Interventions

- **liraglutide** (DRUG)

## Primary Outcomes

- **HbA1c** _(time frame: after 14 weeks treatment)_

## Secondary Outcomes

- **Glycaemic control parameters (fasting plasma glucose, post prandial plasma glucose) after 14-week treatment**
- **Body weight after 14 weeks.**
- **Safety and tolerability**

## Locations (1)

- Novo Nordisk Investigational Site, Tokyo, Japan

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|tokyo||japan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00154414.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00154414*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*